Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Adeena Musheer has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    MARROW-MECH: AI-Assisted Identification of Mechanistic Biomarkers Distinguishing Adaptive Somatic Rescue from Malignant Clonal Evolution in GATA2 Deficiency and SAMD9/SAMD9L Syndromes

    by Yan Leyfman, Adeena Musheer, Zara Baloch, Diksha Sanjana Pasnoor, Noam Levi, Taha Kassim Dohadwala, Helena Sanchez Coloma, Gayathri Pramil Menon, Muskan Joshi, Maduri Balasubramanian, et al.

    From the 2026 National Summit on Hematologic Cancers

  • Open Access

    From Frontline Therapy to Relapse: Mapping Generative AI Consensus Across the CLL Treatment Journey

    by Yan Leyfman, Noam Levi, Diksha Sanjana Pasnoor, Adeena Musheer, Zara Baloch, Huseyin Avni Yalcin, Helena Sanchez Coloma, Maduri Balasubramanian, Muskan Joshi, Taha Kassim Dohadwala, et al.

    From the 2026 National Summit on Hematologic Cancers

  • Durvalumab Consolidation After Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer

    by Adeena Musheer, Muhammad S. Mannan, Muhammad W. Khan, Ayesha Junaid, Tuba Basit, Ali Shan Hafeez, Moazzam Shahzad

    Objectives: Durvalumab consolidation following concurrent chemoradiotherapy (CRT) has become the standard of care for patients with unresectable stage III non–small cell lung cancer (NSCLC). However, survival outcomes reported in clinical trials and real-world studies have been inconsistent, making it difficult to understand the efficacy and safety of this treatment modality fully. Our study aims to pool the available evidence to evaluate the impact of durvalumab in patients with unresectable stage III NSCLC. Methods: PubMed, Embase, Cochrane Library, and Web of Science were searched for studies including randomized controlled trials and real-world observational studies that assess durvalumab after definitive CRT in unresectable stage III NSCLC, till January 2026. Data extracted included median overall survival (OS), median progression-free survival (PFS), and survival rates. Random-effects meta-analyses were performed to pool OS and PFS. Results: A total of 3 studies comprising 861 patients with unresectable stage III NSCLC were included. Durvalumab consolidation after definitive CRT showed no statistically significant effect on OS (HR: 1.06, 95% CI: 0.52-2.14; I ²=51.6%; P =0.1268) or PFS (HR: 0.87, 95% CI: 0.45-1.68; I ²=49.6%; P =0.1374). Heterogeneity was moderate for both outcomes. In addition to these primary outcomes, multiple secondary efficacy and safety outcomes were systematically evaluated, including overall response rate and treatment-related adverse effects. Conclusions: Durvalumab consolidation demonstrates a favorable safety profile, but outcomes remain variable across studies. These findings highlight the importance of biomarker-driven patient selection and prospective real-world evaluation to maximize the clinical benefit of durvalumab in unresectable stage III NSCLC.

  • PD-1 Inhibition With Camrelizumab in Cervical Cancer

    by Adeena Musheer, Muhammad S. Mannan, Muhammad W. Khan, Aribah Bhatti, Tuba Basit, Ali Shan Hafeez, Hadiya Javed, Safwan Muhammad

    Objectives: Cervical cancer is the fourth leading cause of cancer mortality in women worldwide. PD-L1 is expressed in 34.4% to 96% of cervical cancers. Camrelizumab is an anti-PD-1 IgG4 antibody with antitumor activity. This study evaluates the efficacy and safety of camrelizumab in cervical cancer. Methods: A systematic search of PubMed, Embase, Web of Science, Cochrane Library, Ovid MEDLINE, and Scopus was performed to identify studies of pathologically confirmed cervical cancer treated with camrelizumab alone or in combination with chemotherapy or VEGFR-TKIs, including apatinib or famitinib. Eligible studies included randomized trials, single-arm trials, cohort studies, and case-control studies. Pooled proportions with 95% CIs were calculated using R version 4.4.1. Heterogeneity was assessed using I 2 , and evidence certainty was evaluated using GRADE. Results: Eight studies comprising 382 patients were included. Camrelizumab was evaluated as monotherapy, with chemotherapy, or with VEGFR-TKIs. The pooled objective response rate (ORR) was 0.62 (95% CI: 0.32-0.85). The disease control rate (DCR), assessed in 7 studies including 297 patients, was 0.83 (95% CI: 0.60-0.94). The pooled partial response (PR) rate was 0.45 (95% CI: 0.29-0.62), while the complete response (CR) rate was 0.15 (95% CI: 0.10-0.23). Progressive disease (PD) outcomes were reported in a cohort of 297 patients, corresponding to a proportion of 0.16 (95% CI: 0.06-0.36), and stable disease (SD) demonstrated a pooled proportion of 0.30 (95% CI: 0.19-0.44). Commonly reported adverse events included neutropenia, anemia, leukopenia, hypertension, lymphopenia, and myelosuppression. Conclusions: Camrelizumab demonstrates clinically meaningful antitumor activity in cervical cancer, particularly in combination regimens, though toxicity requires careful monitoring.

  • Impact of Thrombopoietin Receptor Agonists on Platelet Transfusion Requirements in Myelodysplastic Syndromes: An Updated Systematic Review and Meta-Analysis

    by Nouman Aziz, Waseem Nabi, Hafiz Muhammad Umer, Faiza Khan, Hira Habib, Adeena Musheer, Sukhrob Makhkamov, Seyed Mohammad Nahidi, Roha Saeed Memon, Faiz Anwer, et al.


  • Open Access

    The Use of Proton Pump Inhibitors and COVID-19: A Systematic Review and Meta-Analysis

    by Kaneez Fatima, Talal Almas, Shan Lakhani, Arshia Jahangir, Abdullah Ahmed, Ayra Siddiqui, Aiman Rahim, Saleha Ahmed Qureshi, Zukhruf Arshad, Shilpa Golani, et al.

    COVID-19 has proved to be a serious, and consequential disease that has affected millions of people globally. Previously, the adverse effects of proton pump inhibitors (PPI) have been observed with increasing the risk of pneumonia and COVID-19. This meta-analysis aims to address the relationship between the use of PPI and the severity of COVID-19 infection. We conducted a systemic literature search from PUBMED, Science Direct, and Cinahl from December 2019 to January 2022. Published and unpublished randomized control trials and cohort studies were included. Review Manager was used for all statistical analyses. In total, 14 studies were included in this systemic review and meta-analysis. Outcomes of interest include: (1) susceptibility of COVID-19 infection and (2) severity of COVID-19 (defined as the composite of poor outcomes: ICU admission, need for oxygen therapy, need for a ventilator, or death), and (3) mortality due to COVID-19. PPI use was marginally associated with a nominal but statistically significant increase in the risk of COVID-19 infection (OR 1.05 [1.01, 1.09]; I2 97%, p = 0.007). PPI use also increased the risk of the composite poor outcome (OR 1.84 [1.71, 1.99]; I2 98%, p < 0.00001) and mortality (OR 1.12 [1.00, 1.25]; I2 84%, p = 0.05) in patients with COVID-19.